Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$39.33 USD
+0.90 (2.34%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $39.36 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BHVN 39.33 +0.90(2.34%)
Will BHVN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BHVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHVN
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
BHVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Other News for BHVN
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Biohaven(BHVN) Shares Cross Above 200 DMA
Tesla downgraded, Spotify upgraded: Wall Street's top analyst calls
Biohaven initiated with bullish view at Morgan Stanley, here's why
Morgan Stanley starts Biohaven at overweight, cites broad pipeline